Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Engineering monoclonal antibodies to enhance drugability: A case study

In this application note, we compare stability data predicted by DSC of different engineered antibodies with SEC-HPLC data from accelerated stability studies. For the engineered proteins studied, there is a correlation between decreased thermostabilty based on DSC data, and greater aggregation formation during accelerated stability studies.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

Related White Papers

It's a matter of taste!

| Contributed by GalenIQ

Investigating the Effects of Excipients on the Earliest Stages of Aggregation - Aggregation Inhibition by Arginine

| Contributed by Malvern Panalytical

Generic Nasal Spray Design

| Contributed by Malvern Panalytical

Newsletter

Send me the latest from The Medicine Maker.

Sign up now

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register